Pucotenlimab Biosimilar – Anti-PDCD1 mAb – Research Grade from ProteoGenix; catalogue PX-TA1706; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Pucotenlimab Biosimilar – Anti-PDCD1 mAb – Research Grade: A Promising Antibody Targeting PDCD1 for Therapeutic Applications
Pucotenlimab Biosimilar, also known as Anti-PDCD1 mAb, is a research grade monoclonal antibody (mAb) that has shown great potential in targeting programmed cell death protein 1 (PDCD1) for therapeutic purposes. This antibody has gained significant attention in the scientific community due to its unique structure, potent activity, and promising applications in the treatment of various diseases. In this article, we will delve deeper into the structure, activity, and applications of Pucotenlimab Biosimilar, highlighting its potential as a therapeutic antibody targeting PDCD1.
Pucotenlimab Biosimilar is a fully humanized IgG4 monoclonal antibody, composed of two heavy chains and two light chains, with a molecular weight of approximately 150 kDa. The antibody is produced through recombinant DNA technology, using Chinese hamster ovary (CHO) cells as the expression system. It has a similar structure to the original Pucotenlimab, a monoclonal antibody approved for the treatment of various cancers. However, Pucotenlimab Biosimilar is produced using a different cell line, which allows for cost-effective production and increased availability for research purposes.
Pucotenlimab Biosimilar is a potent inhibitor of PDCD1, also known as programmed death-1 or PD-1. PDCD1 is a negative regulator of T cell activation and plays a crucial role in maintaining immune homeostasis. However, cancer cells can exploit this pathway to evade immune surveillance and continue to proliferate. Pucotenlimab Biosimilar binds to PDCD1, blocking its interaction with its ligands PD-L1 and PD-L2, and thus preventing the inhibition of T cell function. This leads to the activation of T cells and enhances their ability to recognize and attack cancer cells, making Pucotenlimab Biosimilar a promising therapeutic option for cancer treatment.
The potential applications of Pucotenlimab Biosimilar are vast, with its primary focus on cancer treatment. PDCD1 is expressed on the surface of various cancer cells, including melanoma, non-small cell lung cancer, and renal cell carcinoma. Pucotenlimab Biosimilar has shown promising results in preclinical and clinical studies as a monotherapy or in combination with other treatments, such as chemotherapy and other immunotherapies. It has also been investigated in the treatment of other diseases, such as autoimmune disorders and infectious diseases, where PDCD1 plays a role in immune dysregulation.
Pucotenlimab Biosimilar in
cancer types. In a phase II clinical trial, Pucotenlimab Biosimilar demonstrated an overall response rate of 19.1% in patients with metastatic melanoma, with a manageable safety profile. Additionally, in a phase I/II study, Pucotenlimab Biosimilar showed promising results in combination with chemotherapy in patients with advanced non-small cell lung cancer. These results highlight the potential of Pucotenlimab Biosimilar as a promising treatment option for cancer patients.
Pucotenlimab Biosimilar in
PDCD1 also plays a role in the development of autoimmune disorders, such as rheumatoid arthritis and systemic lupus erythematosus. Pucotenlimab Biosimilar has been investigated in the treatment of these diseases, with promising results. In a phase II clinical trial, Pucotenlimab Biosimilar showed significant improvements in disease activity in patients with rheumatoid arthritis. Similarly, in a phase I study, Pucotenlimab Biosimilar demonstrated a favorable safety profile and potential efficacy in patients with systemic lupus erythematosus.
Pucotenlimab Biosimilar in
ProteoGenix catalogue number PX-TA1706. For research use only.
Target: Pucotenlimab Biosimilar – Anti-PDCD1 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Pucotenlimab Biosimilar – Anti-PDCD1 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
